Is HURA or CTNM more profitable?

Contineum Therapeutics' return on equity of -27.09% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.12% -105.38% Contineum Therapeutics N/A -27.09% -25.64%

Is HURA or ARVN more profitable?

TuHURA Biosciences has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.12% -105.38% Arvinas -247.54% -44.38% -28.38%

Which has higher earnings & valuation, HURA or IMMX?

Immix Biopharma is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TuHURA Biosciences N/A N/A -$30.05M -$0.61 N/A Immix Biopharma N/A N/A -$29.44M -$0.92 N/A

Is HURA or IMMX more profitable?

Immix Biopharma's return on equity of -73.24% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.12% -105.38% Immix Biopharma N/A -73.24% -59.20%

TuHURA Biosciences (HURA) Competitors

$2.38 0.00 (0.00%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$2.39 +0.01 (+0.42%)

As of 07:02 AM Eastern

Compare

HURA vs. ALT, PROK, CTNM, ARVN, and IMMX

Should you buy TuHURA Biosciences stock or one of its competitors? MarketBeat compares TuHURA Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TuHURA Biosciences include Altimmune (ALT), ProKidney (PROK), Contineum Therapeutics (CTNM), Arvinas (ARVN), and Immix Biopharma (IMMX). These companies are all part of the "pharmaceutical products" industry.

How does TuHURA Biosciences compare to Altimmune?

Altimmune (NASDAQ:ALT) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

In the previous week, Altimmune had 1 more articles in the media than TuHURA Biosciences. MarketBeat recorded 2 mentions for Altimmune and 1 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 1.68 beat Altimmune's score of 0.71 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Altimmune	Positive
TuHURA Biosciences	Very Positive

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 1.6% of Altimmune shares are owned by insiders. Comparatively, 6.1% of TuHURA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

TuHURA Biosciences has lower revenue, but higher earnings than Altimmune. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	14,244.93	-$88.09M	-$0.93	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

Altimmune has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market.

Altimmune currently has a consensus target price of $15.71, suggesting a potential upside of 436.32%. TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 278.15%. Given Altimmune's stronger consensus rating and higher probable upside, equities analysts clearly believe Altimmune is more favorable than TuHURA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

TuHURA Biosciences has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
TuHURA Biosciences	N/A	-156.12%	-105.38%

Summary

Altimmune beats TuHURA Biosciences on 10 of the 15 factors compared between the two stocks.

How does TuHURA Biosciences compare to ProKidney?

ProKidney (NASDAQ:PROK) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

51.6% of ProKidney shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 39.8% of ProKidney shares are held by company insiders. Comparatively, 6.1% of TuHURA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ProKidney has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market.

TuHURA Biosciences has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-8,131.50%	N/A	-21.39%
TuHURA Biosciences	N/A	-156.12%	-105.38%

In the previous week, ProKidney had 1 more articles in the media than TuHURA Biosciences. MarketBeat recorded 2 mentions for ProKidney and 1 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 1.68 beat ProKidney's score of 0.62 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
ProKidney	Positive
TuHURA Biosciences	Very Positive

ProKidney presently has a consensus price target of $12.00, indicating a potential upside of 674.19%. TuHURA Biosciences has a consensus price target of $9.00, indicating a potential upside of 278.15%. Given ProKidney's higher probable upside, analysts clearly believe ProKidney is more favorable than TuHURA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

TuHURA Biosciences has lower revenue, but higher earnings than ProKidney. TuHURA Biosciences is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	526.06	-$68.99M	-$0.53	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

Summary

ProKidney beats TuHURA Biosciences on 11 of the 16 factors compared between the two stocks.

How does TuHURA Biosciences compare to Contineum Therapeutics?

TuHURA Biosciences (NASDAQ:HURA) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

TuHURA Biosciences has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

TuHURA Biosciences presently has a consensus target price of $9.00, indicating a potential upside of 278.15%. Contineum Therapeutics has a consensus target price of $20.00, indicating a potential upside of 37.27%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe TuHURA Biosciences is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Contineum Therapeutics had 1 more articles in the media than TuHURA Biosciences. MarketBeat recorded 2 mentions for Contineum Therapeutics and 1 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 1.68 beat Contineum Therapeutics' score of 0.96 indicating that TuHURA Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
TuHURA Biosciences	Very Positive
Contineum Therapeutics	Positive

TuHURA Biosciences has higher earnings, but lower revenue than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
Contineum Therapeutics	$50M	10.90	-$59.98M	-$1.95	N/A

0.6% of TuHURA Biosciences shares are owned by institutional investors. 6.1% of TuHURA Biosciences shares are owned by company insiders. Comparatively, 7.9% of Contineum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Contineum Therapeutics' return on equity of -27.09% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
Contineum Therapeutics	N/A	-27.09%	-25.64%

Summary

TuHURA Biosciences beats Contineum Therapeutics on 8 of the 14 factors compared between the two stocks.

How does TuHURA Biosciences compare to Arvinas?

TuHURA Biosciences (NASDAQ:HURA) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 6.1% of TuHURA Biosciences shares are held by company insiders. Comparatively, 7.3% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

TuHURA Biosciences has higher earnings, but lower revenue than Arvinas. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
Arvinas	$262.60M	2.03	-$80.80M	-$3.32	N/A

In the previous week, Arvinas had 1 more articles in the media than TuHURA Biosciences. MarketBeat recorded 2 mentions for Arvinas and 1 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 1.68 beat Arvinas' score of 1.24 indicating that TuHURA Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
TuHURA Biosciences	Very Positive
Arvinas	Positive

TuHURA Biosciences has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market. Comparatively, Arvinas has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market.

TuHURA Biosciences currently has a consensus price target of $9.00, suggesting a potential upside of 278.15%. Arvinas has a consensus price target of $15.42, suggesting a potential upside of 86.42%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe TuHURA Biosciences is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

TuHURA Biosciences has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
Arvinas	-247.54%	-44.38%	-28.38%

Summary

Arvinas beats TuHURA Biosciences on 9 of the 15 factors compared between the two stocks.

How does TuHURA Biosciences compare to Immix Biopharma?

TuHURA Biosciences (NASDAQ:HURA) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 6.1% of TuHURA Biosciences shares are owned by insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

TuHURA Biosciences has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

Immix Biopharma's return on equity of -73.24% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
Immix Biopharma	N/A	-73.24%	-59.20%

Immix Biopharma is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A

In the previous week, Immix Biopharma had 3 more articles in the media than TuHURA Biosciences. MarketBeat recorded 4 mentions for Immix Biopharma and 1 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 1.68 beat Immix Biopharma's score of 0.79 indicating that TuHURA Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
TuHURA Biosciences	Very Positive
Immix Biopharma	Positive

TuHURA Biosciences presently has a consensus target price of $9.00, suggesting a potential upside of 278.15%. Immix Biopharma has a consensus target price of $20.67, suggesting a potential upside of 93.51%. Given TuHURA Biosciences' higher possible upside, equities analysts plainly believe TuHURA Biosciences is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Immix Biopharma beats TuHURA Biosciences on 8 of the 12 factors compared between the two stocks.

Get TuHURA Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HURA vs. The Competition

Export

Metric	TuHURA Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$151.57M	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-3.90	20.98	26.94	24.38
Price / Sales	N/A	311.10	521.23	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	7.00	8.54	10.89	6.33
Net Income	-$30.05M	$23.83M	$3.59B	$331.02M
7 Day Performance	4.39%	-2.77%	-1.53%	-0.33%
1 Month Performance	4.85%	5.85%	2.72%	-1.29%
1 Year Performance	3.48%	52.15%	28.47%	21.30%

TuHURA Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HURA TuHURA Biosciences	2.9281 of 5 stars	$2.38 flat	$9.00 +278.2%	+2.1%	$151.57M	N/A	N/A	N/A
ALT Altimmune	2.3061 of 5 stars	$3.01 -2.4%	$15.71 +422.9%	-31.2%	$586.33M	$40K	N/A	50	Gap Down
PROK ProKidney	1.6443 of 5 stars	$1.90 -4.8%	$9.00 +374.9%	-58.0%	$581.47M	$889K	N/A	3	News Coverage
CTNM Contineum Therapeutics	1.7245 of 5 stars	$15.04 -3.2%	$20.00 +33.0%	+290.6%	$562.53M	$50M	N/A	31	Gap Up
ARVN Arvinas	3.4161 of 5 stars	$8.53 +0.9%	$15.42 +80.7%	+5.1%	$557.65M	$262.60M	N/A	420	Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HURA) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TuHURA Biosciences (HURA) Competitors

HURA vs. ALT, PROK, CTNM, ARVN, and IMMX

How does TuHURA Biosciences compare to Altimmune?

Summary

How does TuHURA Biosciences compare to ProKidney?

Summary

How does TuHURA Biosciences compare to Contineum Therapeutics?

Summary

How does TuHURA Biosciences compare to Arvinas?

Summary

How does TuHURA Biosciences compare to Immix Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA vs. The Competition

TuHURA Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TuHURA Biosciences (HURA) Competitors

HURA vs. ALT, PROK, CTNM, ARVN, and IMMX

How does TuHURA Biosciences compare to Altimmune?

Does the media refer more to ALT or HURA?

Do institutionals & insiders hold more shares of ALT or HURA?

Which has stronger valuation and earnings, ALT or HURA?

Which has more risk and volatility, ALT or HURA?

Do analysts recommend ALT or HURA?

Is ALT or HURA more profitable?

Summary

How does TuHURA Biosciences compare to ProKidney?

Do insiders and institutionals have more ownership in PROK or HURA?

Which has more risk and volatility, PROK or HURA?

Is PROK or HURA more profitable?

Does the media prefer PROK or HURA?

Do analysts rate PROK or HURA?

Which has stronger earnings & valuation, PROK or HURA?

Summary

How does TuHURA Biosciences compare to Contineum Therapeutics?

Which has more risk and volatility, HURA or CTNM?

Do analysts prefer HURA or CTNM?

Does the media favor HURA or CTNM?

Which has higher valuation and earnings, HURA or CTNM?

Do insiders & institutionals have more ownership in HURA or CTNM?

Is HURA or CTNM more profitable?

Summary

How does TuHURA Biosciences compare to Arvinas?

Do insiders and institutionals believe in HURA or ARVN?

Which has preferable valuation and earnings, HURA or ARVN?

Does the media favor HURA or ARVN?

Which has more risk & volatility, HURA or ARVN?

Do analysts prefer HURA or ARVN?

Is HURA or ARVN more profitable?

Summary

How does TuHURA Biosciences compare to Immix Biopharma?

Do insiders and institutionals have more ownership in HURA or IMMX?

Which has more volatility and risk, HURA or IMMX?

Is HURA or IMMX more profitable?

Which has higher earnings & valuation, HURA or IMMX?

Does the media favor HURA or IMMX?

Do analysts prefer HURA or IMMX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA vs. The Competition

TuHURA Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools